Skip to main content

Entera Bio Ltd.

corporate_fare Company Profile

Entera Bio Ltd.

ENTX·NASDAQ·Life Sciences·CIK 0001638097

Entera is a clinical stage company focused on developing oral tablet forms of peptide or protein replacement therapies for chronic medical conditions. The company aims to address underserved conditions where oral administration of protein therapy could significantly change treatment. Most protein therapies are currently given through frequent intravenous, subcutaneous, or intramuscular injections, which can be challenging for patients with chronic diseases. Entera's pipeline includes oral peptides targeting PTH(1-34), GLP-1/Glucagon, and GLP-2. The company uses its N-Tab® platform, designed to stabilize large (4kD+) hydrophilic peptides in the gastrointestinal tract and promote their absorption into the bloodstream. The most advanced product candidate is EB613 (oral teriparatide, or oral PTH[1-34]), which is being developed as the first oral, osteoanabolic (bone building) tablet treatment for osteoporosis. EB613 is being developed under a 505(b)(2) application, referencing Forteo® (teriparatide SC injection, Eli Lilly). Forteo® was initially approved by the FDA in 2002 for postmenopausal women with osteoporosis at high risk of fracture, and later for men with osteoporosis and osteoporosis associated with sustained systemic glucocorticoid therapy. Forteo® has been in clinical use for over 20 years. Osteoporosis is a chronic disorder where bone resorption exceeds formation, leading to decreased bone strength and increased fracture susceptibility. It causes over two million fractures annually in the United States. After age 50, one in three women and one in five men will experience an osteoporosis-related fracture. Studies indicate that up to 20-24% of hip fracture patients die within one year.

Entera Bio Ltd. (NASDAQ:ENTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 30 items for ENTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-14, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for ENTX spans DEF 14A, PRE 14A, 424B3, 10-Q.

Recent high-impact activity:

  • Entera Bio Seeks Shareholder Approval for 13.9M Share Plan Increase and Executive Top-up Grants
  • Entera's Oral Osteoporosis Drug Shows Stronger Bone Gains in High-Risk Patients, Phase 3 Design Unveiled
  • Entera Bio Seeks Approval for 13.9M Share Plan Increase and CEO/CFO/COO/R&D Top-up Grants
  • Entera Bio Registers Resale of 134.8M Shares from $275M Private Placement
  • Entera Bio Lifts Going Concern Warning, Projects Cash Runway to 2030 After $275M Placement

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$42K
Net Income
-$11.44M
Diluted EPS
$0.25
Op. Cash Flow
-$7.37M
Free Cash Flow
-$7.48M
Gross Profit
$0
Operating Income
-$11.53M
Cash & Equivalents
$7.11M
Debt / Equity
0.00×
Net Margin
-272.36×
Shares Outstanding
46.18M sh
Source: 10-K · filed 2026-03-27 · accession 0001178913-26-001797

Short Interest & Short Volume

15.59 days to cover

FINRA reported short interest of 7,070,019 shares in ENTX as of the October 30, 2026 settlement, a 27.4% increase from the prior period — about 15.6 days to cover at its recent average daily volume. On November 20, 2026, 52.2% of ENTX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)7,070,019 shares as of October 30, 2026
Change vs prior period▲ 27.4%
Days to cover15.59 at avg daily volume of 453,441
Daily short volume (FINRA facilities)52.2% of 199,411 shares on November 20, 2026
5-day average short volume50.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for ENTX, detected from its recent SEC filings · based on capital-structure filings through 2026-07-28.

1 shelf registration

$275M Private Placement Closed · Extreme Dilution for Existing Holders

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with E →
$3.3 -0.15% today
52-week range · as of 2026-10-14 $0.91 – $4.2
Market cap
$575.53M
Volume
469.1K (1.2× avg)
3-mo avg 401.9K
Live data · 2026-11-22 03:31 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ENTX - Latest Insights

ENTX
Oct 14, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $2.52
Real-time Price: $3.30 info
Change: +$0.780 (+31%) info
Market Cap: $575.525M info
ENTX
Oct 13, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.60
Real-time Price: $3.30 info
Change: +$0.700 (+27%) info
Market Cap: $575.525M info
ENTX
Sep 23, 2026, 4:05 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $2.81
Real-time Price: $3.30 info
Change: +$0.490 (+17%) info
Market Cap: $575.525M info
ENTX
Aug 28, 2026, 4:13 PM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $3.03
Real-time Price: $3.30 info
Change: +$0.270 (+9%) info
Market Cap: $575.525M info
ENTX
Aug 07, 2026, 4:09 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.85
Real-time Price: $3.30 info
Change: +$0.450 (+16%) info
Market Cap: $575.525M info
ENTX
Aug 07, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.78
Real-time Price: $3.30 info
Change: +$0.520 (+19%) info
Market Cap: $575.525M info
ENTX
Aug 04, 2026, 7:07 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $2.78
Real-time Price: $3.30 info
Change: +$0.520 (+19%) info
Market Cap: $575.525M info
ENTX
Aug 03, 2026, 7:33 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.96
Real-time Price: $3.30 info
Change: +$0.3371 (+11%) info
Market Cap: $575.525M info
ENTX
Jul 28, 2026, 4:12 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.23
Real-time Price: $3.30 info
Change: +$0.070 (+2%) info
Market Cap: $575.525M info
ENTX
Jul 27, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $2.98
Real-time Price: $3.30 info
Change: +$0.319 (+11%) info
Market Cap: $575.525M info
ENTX
Jun 22, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.33
Real-time Price: $3.30 info
Change: +$1.97 (+148%) info
Market Cap: $575.525M info
ENTX
Jun 16, 2026, 8:33 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.23
Real-time Price: $3.30 info
Change: +$2.07 (+168%) info
Market Cap: $575.525M info
ENTX
Jun 03, 2026, 4:14 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $1.22
Real-time Price: $3.30 info
Change: +$2.08 (+170%) info
Market Cap: $575.525M info
ENTX
Jun 03, 2026, 4:06 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $1.22
Real-time Price: $3.30 info
Change: +$2.08 (+170%) info
Market Cap: $575.525M info
ENTX
May 28, 2026, 8:50 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.25
Real-time Price: $3.30 info
Change: +$2.05 (+164%) info
Market Cap: $575.525M info
ENTX
May 14, 2026, 4:08 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $1.32
Real-time Price: $3.30 info
Change: +$1.98 (+150%) info
Market Cap: $575.525M info
ENTX
May 08, 2026, 4:20 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $1.27
Real-time Price: $3.30 info
Change: +$2.03 (+160%) info
Market Cap: $575.525M info
ENTX
May 08, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.27
Real-time Price: $3.30 info
Change: +$2.03 (+160%) info
Market Cap: $575.525M info
ENTX
May 08, 2026, 4:06 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $1.30
Real-time Price: $3.30 info
Change: +$2.00 (+154%) info
Market Cap: $575.525M info
ENTX
May 08, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.27
Real-time Price: $3.30 info
Change: +$2.03 (+160%) info
Market Cap: $575.525M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets